LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX), a biopharmaceutical company focused on the development and commercialization of products for respiratory, inflammatory and critical care diseases, announced today the publication of a peer-reviewed article based on a study of zileuton, the Company’s 5-lipoxygenase (5-LO) inhibitor. The study suggests that combining zileuton (400 or 600 mg QID) with a low-dose inhaled corticosteroid (ICS) improves pulmonary lung function and may be an effective therapeutic approach to achieving asthma control in patients with moderate to severe persistent disease
